Edition:
United States

North China Pharmaceutical Co Ltd (600812.SS)

600812.SS on Shanghai Stock Exchange

5.12CNY
1:40am EST
Change (% chg)

¥-0.01 (-0.19%)
Prev Close
¥5.13
Open
¥5.12
Day's High
¥5.14
Day's Low
¥5.10
Volume
2,821,818
Avg. Vol
4,600,800
52-wk High
¥7.60
52-wk Low
¥4.96

Select another date:

Fri, Oct 20 2017

BRIEF-North China Pharmaceutical to issue up to 2 bln yuan commercial paper

* Says it plans to issue up to 2.0 billion yuan ($302.20 million) commercial paper

BRIEF-North China Pharmaceutical issues 2017 second tranche corporate bonds worth 290 mln yuan

* Says it issued 2017 second tranche corporate bonds worth 290 million yuan

BRIEF-North China Pharmaceutical sets coupon rate of 2017 2st tranche corporate bonds at 6.2 pct

* Says it sets coupon rate of 2017 2st tranche corporate bonds at 6.2 percent

BRIEF-North China Pharmaceutical to issue 290 mln yuan 4-year bonds

* Says to issue 290 million yuan ($43.97 million) 4-year bonds

BRIEF-North China Pharmaceutical to pay A shares annual div for FY 2016 on Aug. 25

* Says it will pay cash dividend of 0.02 yuan(before tax)/share for 2016 to shareholders of record on Aug. 24

BRIEF-North China Pharmaceutical issues 2017 2nd series super short-term debentures worth 500 mln yuan

* Says it issues 2017 the second series super short-term debentures worth 500 million yuan, with coupon rate of 5.08 percent and maturity date on Jan. 29, 2018

BRIEF-North China Pharmaceutical issues 210 mln yuan worth of corporate bonds

* Says it issues 210 mln yuan worth of 2017 public offering corporate bonds

BRIEF-North China Pharmaceutical sets coupon rate for 2017 corporate bonds at 6.5 pct

* Says it sets coupon rate for 2017 corporate bonds at 6.5 percent

BRIEF-North China Pharmaceutical to issue up to 500 mln yuan 4-year bonds

* Says to issue up to 500 million yuan ($74.10 million) 4-year bonds

BRIEF-North China Pharmaceutical's unit receives GMP certificate

* Says co's pharmacy unit received goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration, for its sterile APIs (amoxicillin/sulbactam), with the valid period is until June 22, 2022

Select another date: